Edition:
India

Prometic Life Sciences Inc (PLI.TO)

PLI.TO on Toronto Stock Exchange

0.05CAD
17 May 2019
Change (% chg)

$-0.00 (-10.00%)
Prev Close
$0.05
Open
$0.05
Day's High
$0.05
Day's Low
$0.05
Volume
6,037,460
Avg. Vol
2,748,409
52-wk High
$1.01
52-wk Low
$0.04

Summary

Name Age Since Current Position

Simon Best

61 2018 Interim Chief Executive Officer

Bruce Pritchard

2017 Interim Chief Financial Officer, Chief Operating Officer

John Moran

71 2014 Chief Medical Officer, Director

Patrick Sartore

2015 Chief Legal Officer and Corporate Secretary

Gary Bridger

2019 Director

Stefan Clulow

47 2014 Non-Independent Director

Charles Kenworthy

60 2013 Non-Independent Director

Neil Klompas

2019 Director

Zachary Newton

2018 Director

Timothy Wach

2019 Director

Andrew Bishop

2015 Independent Director

Kenneth Galbraith

55 2016 Independent Director

Paul Mesburis

48 2009 Independent Director

Frederic Dumais

2017 Senior Director, Communications and Investor relations

Biographies

Name Description

Simon Best

Prof. Simon Geoffrey Best is Interim Chief Executive Officer of the company, He was Independent Chairman of the Board of the Company. Prof. Best is a seasoned veteran of the global Lifescience Industry with experience, both as a Founder, Chief Executive Officer and Chairman or board member of entrepreneurial companies and as a Chairman or board member of major industry bodies and public sector institutions in the UK, USA, Europe, Asia and Latin America including the UK BioIndustry Association (BIA) and the US Biotechnology Industry Organization (BIO). He is also an experienced Angel, Venture Capital and Private Equity investor. In 1999, the World Economic Forum nominated him a Global Leader of Tomorrow and in 2000, a Technology Pioneer of the Year. In 1999, he was nominated as "Science and Technology Venturer of the Year" by the Financial Times. He was awarded the London Business School Alumni Achievement Prize in 2007. He holds an MBA from London Business School and an Honorary Doctorate and B.Mus from York University. In 2007, he was elected a Fellow of the Royal Society of Edinburgh. In 2008, he was awarded an OBE by Queen Elizabeth II and appointed a Visiting Professor of Medicine by the University of Edinburgh. On November 4, 2015, Prof. Best was elected to the board of Evofem Inc., a women's health company based in San Diego. From March 2010 to August 2015, Prof. Best was the Chairman of Edinburgh BioQuarter with responsibility for company formation and technology transfer for the University of Edinburgh. In September 2015, this entity was replaced by Sunergos Innovations Limited. Sunergos was reabsorbed by the University in February 2017 after which Prof. Best continued to serve as a Senior Advisor. Prof. Best held also the position of Chief Executive Officer at Aquapharm Biodiscovery Ltd. (a company in the sector of drug discovery) from May 2010 to November 2012.

Bruce Pritchard

Mr. Bruce Pritchard is Interim Chief Financial Officer, Chief Operating Officer of the Company. Mr. Bruce Pritchard joined PLI as CFO of the UK subsidiary, Prometic BioSciences Ltd. (“PBL”) in 2006 and was promoted CFO of the group in 2008, relinquishing that post in November 2015. He became Chief Operating Officer in August 2014. He is a chartered accountant with many years of experience in general management, operations and corporate accountancy including senior finance positions with biotech and pharmaceutical companies. He has a proven track record of success in strategic acquisitions and in raising debt and equity finance. Mr. Pritchard is a Non-Executive Director and Chair of the Audit Committee of Imanova Limited. A Heriot-Watt University graduate, Mr. Pritchard gained a BA in Accountancy and Computer Science in 1993, he qualified as a Member of the Institute of Chartered Accountants of Scotland in 1996. He was appointed a Fellow of the Institute of Directors in 2014.

John Moran

Dr. John Moran, M.D., FRACP, FACP, FACPE is Chief Medical Officer, Director of ProMetic Life Sciences Inc., since March 1st, 2014. From 2010 until joining the Corporation, Dr. Moran was Vice President, Clinical Affairs - Home modalities at DaVita Healthcare Partners Inc. where he had the overall responsibility for quality of care and related business issues for over 20,000 home dialysis patients in over 1,000 care centers. Previously, Dr. Moran served for eight years as Senior Vice President, Clinical Affairs for Satellite Healthcare. Dr. Moran also served at Baxter Healthcare as Global Medical Director for the Renal Division for five years and for two years as Vice President for Clinical Development and Marketing. Dr. John Moran sits on the board of directors of Intelomed, Inc., a US private company.

Patrick Sartore

Mr. Patrick Sartore is a Chief Legal Officer and Corporate Secretary of the Company. Mr. Patrick Sartore joined Prometic in 2006 as Senior Legal Counsel – Intellectual Property, was nominated Corporate Secretary of the Corporation in 2007. Mr. Sartore held the position of General Counsel and Corporate Secretary from May 2013 to May 2015, at which date he was appointed Chief Legal Officer and Corporate Secretary. Mr. Sartore was previously employed by Univalor Inc. as Legal Counsel and Leger Robic Richard, L.L.P., a firm specializing in Intellectual Property, Corporate and Commercial Law, as an associate attorney. Mr. Sartore has extensive experience in the areas of intellectual property, technology transfer, licensing and commercialization, private and public financing as well as general corporate and commercial law, namely in the biopharmaceutical field. Mr. Sartore graduated from the University of Montreal with a Bachelor of Law (LLB) in 1999 and was called to the Bar of Québec in 2001. Mr. Sartore also holds a Bachelor of Science, with Distinction, from Concordia University.

Gary Bridger

Dr.Gary J. Bridger is Director of the company. Dr.Gary Bridgerhas served as a member of the board of directors of X4 Pharmaceuticals, Inc. sinceOctober 2018. FromFebruary 2015toDecember 2017, Dr. Bridger served as a consultant to Xenon Pharmaceuticals Inc., a biopharmaceutical company, where he previously served as the Executive Vice President of Research and Development fromJanuary 2013toFebruary 2015. FromOctober 2013toOctober 2015, Dr. Bridger served as a Managing Director at Five Corners Capital Inc. FromJune 2010toJune 2012, Dr. Bridger served as a venture partner at Venture West Capital Management, a venture capital firm. FromNovember 2006toDecember 2007, Dr. Bridger served as Senior Vice President of Research and Development of Genzyme Corporation, a biotechnology company, which was acquired by Sanofi, S.A. InJune 1996, Dr. Bridger co-founded AnorMED Inc., a biopharmaceutical company, and was its Vice President of Research and Development and Chief Scientific Officer from 2000 until its acquisition by Genzyme inNovember 2006. Dr. Bridger has served on the board of directors of Aquinox Pharmaceuticals, Inc. since 2013. Dr. Bridger previously served on the board of directors of Alder BioPharmaceuticals, Inc., a biopharmaceutical company, from 2013 to 2016. Dr. Bridger serves on the scientific advisory board of Alectos Therapeutics Inc., a biopharmaceutical company. Dr. Bridger holds a Ph.D. in Organic Chemistry from the University of Manchester Institute of Science and Technology.

Stefan Clulow

Mr. Stefan Clulow is Non-Independent Director of the Company. Mr. Stefan Clulow is Managing Director and Chief Investment Officer of Thomvest Asset Management Inc., a private investment firm. Mr. Clulow sits on the boards of a number of private companies and charitable organizations. Mr. Clulow received a B.A. and an LL.B. from McGill University. He is a member of the State Bar of California and the Law Society of Upper Canada. Mr. Stefan Clulow was nominated by Structured Alpha LP ("Structured Alpha") to the Board, pursuant to a loan agreement entered into between the Corporation, certain of its affiliates, and Thomvest Seed Capital Inc., ("Thomvest") dated as of September 10, 2013, as amended and restated from time to time, and as assigned by Thomvest to its affiliate, Structured Alpha (the "Loan Agreement"). Pursuant to the Loan Agreement, Structured Alpha is entitled to nominate one person for election to the Board.

Charles Kenworthy

Mr. Charles N. Kenworthy is Non-Independent Director of the Company. Mr. Charles N. Kenworthy is Executive Vice-President, Corporate Strategy, NantWorks, LLC since 2011 and President of Nant Capital, LLC. Mr. Kenworthy received his Bachelor of Arts from the University of California, Los Angeles, in 1980 and his Juris Doctorate from the University of San Diego School of Law in 1985. He joined the law firm of Allen Matkins in the mid-1980's and was a partner when he departed in 2006. Thereafter, he joined Abraxis Biosciences, LLC as Executive Vice-President, Corporate Strategy. Mr. Charles N. Kenworthy was nominated to the Board by California Capital Equity, LLC ("CCE") (an affiliate of Abraxis Bioscience International Holding Company, Inc.), pursuant to a securities purchase agreement (the "Purchase Agreement") entered into between the Corporation and Abraxis Bioscience International Holding Company, Inc. on September 3, 2008. Pursuant to the Purchase Agreement, CCE is entitled to nominate one person for election to the Board.

Neil Klompas

Mr. Neil A. Klompas is Director of company. Mr.Neil A. Klompasjoined Zymeworks Inc. inMarch 2007where he currently serves as Chief Financial Officer. Prior to joining Zymeworks, he worked with KPMG LLP inCanadaandthe United States, most recently (from 2005 to 2007) with KPMG's Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice inPrinceton, New Jersey, where he advised on transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, from 2000 to 2005 Mr. Klompas worked with KPMG's Canadian Biotechnology and Pharmaceuticals practice. Mr. Klompas is a Chartered Professional Accountant and is a member of Chartered Professional Accountants ofBritish Columbia. Mr. Klompas also holds a degree in Microbiology & Immunology from theUniversity of British Columbia. He serves on the faculty advisory board for Biotechnology and Chemistry for Camosun College and as a member of the board of directors of Ovensa Inc., a private biotechnology company.

Zachary Newton

Timothy Wach

Mr. Timothy Wach is Director of the company. Mr.Timothy Wachis Managing Director and Board Member of Taxand sinceJanuary 2015. Mr. Wach is recognised as a leading Canadian lawyer in taxation and frequently publishes papers for research organisations and academic purposes. In 1989, Mr. Wach joined Gowling Lafleur Henderson LLP, as an associate and was a partner from 1992 to 2014, where he specialised in mergers, acquisitions, financings and international tax with focus on the private equity and energy sectors. While a partner of Gowlings, Mr. Wach was on the Gowlings Executive Committee and served as leader of the Firm's National Tax Practice Group and of the Toronto Tax Practice Group. Mr. Wach also has extensive experience in government relations and tax policy, having twice served in the Tax Policy Branch of the Canadian Department of Finance inOttawa, most recently as Director of Legislative Development and Chief Legislative Counsel from 2009 to 2011. In that role, he chaired the Interdepartmental Legislation Review Committee, the committee responsible for the preparation ofCanada'sfederal income tax legislation for submission to Parliament. He also appeared regularly as a witness on behalf of the Department of Finance before the House of Commons Standing Committee on Finance and the Senate Standing Committee on National Finance when those committees considered tax policy matters.

Andrew Bishop

Mr. Andrew Bishop serves as Independent Director of the Company. Mr. Andrew Bishop is a Partner and Co-Founder of Bingley Capital Inc., and brings over 20 years of experience in advising biotech and health care companies. He has worked on over 100 financing and M&A transactions over his career. Prior to establishing Bingley Capital in 2009, he held senior roles in investment banking, including Head of Health Care Investment Banking at HSBC Securities (Canada) Inc., where he covered biotech, pharma, and specialty pharma companies. He started his career in investment banking focused on companies in Quebec. For the past nine years, Mr. Bishop served as a Director and Chair of Willow Breast & Hereditary Cancer Support, a not-for-profit organization focused on breast and hereditary cancer. Mr. Bishop received an International M.B.A. (with Distinction) from the Schulich School of Business at York University, and a Bachelor of Arts in Political Science and Economics from McGill University. He also received his Chartered Financial Analyst designation.

Kenneth Galbraith

Mr. Kenneth H. Galbraith is Independent Director of the Company. Mr. Galbraith is the Managing Director of Five Corners Capital. He joined Ventures West as a General Partner in 2007 and led the firm's biotech practice prior to founding Five Corners Capital in 2013 to continue managing the Ventures West investment portfolio. Mr. Galbraith is a wellknown and active member of the North American life sciences community with over 30 years of experience acting as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Previously, Mr. Galbraith served as the Chairman and Interim CEO of AnorMED, a biopharmaceutical company focused on new therapeutic products in hematology, HIV and oncology, until its sale to Genzyme Corp. in a cash transaction worth almost US$600 million. Starting in the biotech sector in 1987, Mr. Galbraith spent 13 years in senior management with QLT Inc., a global biopharmaceutical company specializing in developing treatments for eye diseases and oncology, retiring in 2000 from his position as Executive VP and CFO when QLT's market capitalization exceeded US$5 billion. He has served on the board of directors of several public and private biotechnology companies, including Zymeworks, Angiotech Pharmaceuticals (ANPI), Aquinox (AQXP), Alder Pharmaceuticals (ALDR), Tekmira (TKMR) and Cardiome Pharma (CRME). He currently serves on the Board of Directors of Macrogenics (MGNX) and Profound Medical. Mr. Galbraith earned a Bachelor of Commerce (Honours) degree from the University of British Columbia in 1985 and appointed a Fellow of the Chartered Accountants of BC in 2013.

Paul Mesburis

Mr. Paul Mesburis is Independent Director of ProMetic Life Sciences Inc. Mr. Mesburis is the Managing Principal of Empyrean Capital, and has more than twenty years of international experience in financial and capital markets. His capital markets experience encompasses senior roles for both buy-side and sell-side firms. On the buy-side, he has managed portfolios for global investment strategies in both debt and equities. On the sell-side, his experience includes senior roles in mergers and acquisitions, investment banking, and institutional equity research at HSBC Securities, Scotiabank Global Banking and Markets and Deutsche Bank Securities. His views on investments have been quoted in the media, including Report on Business of The Globe and Mail and the Financial Post, as well as the subject of features on BNN - Business News Network. In 2012, he was honoured with a Canadian Lipper Fund Award which recognizes funds that have excelled in delivering consistently strong risk-adjusted performance, relative to their peers. He received his Master of Business Administration degree from the Schulich School of Business at York University, his Bachelor of Arts degree from the University of Toronto, and has completed Executive Education at Harvard Business School. Mr. Mesburis holds the Chartered Professional Accountant (Ontario), Certified Public Accountant (Illinois), and a Chartered Financial Analyst designations. He is a member of the Institute of Corporate Directors. Mr. Mesburis serves on the board of directors and is the Chair of the Audit Committees of Avivagen Inc. and EEStor Corp. In addition, he is the Lead Director of Avivagen Inc. and Co-Chair of EEStor Corp.

Frederic Dumais

Basic Compensation